Mycoplasma Testing Market

Mycoplasma Testing Market by Products (Instruments, Kit & Reagents [PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, and Others], and Services), Technology (PCR, ELISA, Direct Assay, and Microbial Culture), Applications (Cell Line Testing, Virus Testing, End Of Production Cells Testing, and Others), End-users (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, And Forecast 2021 – 2028

  • Report ID: HC-1751
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 215
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global mycoplasma testing market size was valued at USD 708.26 million in 2020 and is projected to expand at a high CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising R&D investments and increasing cell culture contamination. Growing introduction of novel technology from key players is projected to fuel the market growth.

Mycoplasma Testing Market

With the limitation of cell cultural methods, the development and identification of accurate mycoplasma tests has been an important need in the recent years. The tests offer some major advantages such as cycle time reduction, high sensitivity, ability to identify wide range of mycoplasma species, and minimum production time besides reducing the spread of contamination. One of the alternate methods for culture-based testing is Nucleic Acid-based Technology (NAT), which provides faster detection of mycoplasma in cell culture. American Type Culture Collection in 2018 launched its new Polymerase Chain Reaction (PCR) service to enhance in finding contaminants in mycoplasma cell cultures.

Many government authorities are supporting biotechnological and pharmaceutical sectors to expand their research activities The US Food and Drug Administration (FDA) in April 2019 introduced a policy to alter the regulations that were affecting testing method used in detection of mycoplasma. According to the agency, this regulation prevented use of other testing methods, which proved to be in the improvement in mycoplasma detection tests. There are more than 190 mycoplasma species identified and out of which, only eight are dominating as they occupy around 96% of cell culture contaminations. For growing number of cell culture contamination, some factors are responsible such as cross-contamination due to faulty or broken laminar flow, dust, practices and aerosols. Additionally, the research works in laboratories is badly affected by mycoplasma contamination and testing of theses bacteria is required for generation of robust data in the field of biomedical research.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising concerns on cell culture contamination is one of the key drivers for the mycoplasma testing market growth.
  • Rising adoption of advanced technology and growing demand for accurate, affordable and fast testing are estimated to drive the market growth.
  • Increasing funding from government for R&D activities and existing vast application of mycoplasma testing products are key factors boosting the market.
  • Rapid growth of many biotechnological, pharmaceutical, and academic institutes and growing outsourcing functions such as clinical trial management, drug discovery to CROs, R&D, and manufacturing are creating immense opportunities for the market players.
  • Restriction entry for new entrants due to high degree of consolidation results in limited investments. This is projected to hamper the growth of the market.

Scope of the Report

The report on the mycoplasma testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Mycoplasma Testing  Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Instruments, Kit & Reagents [PCR Assays, Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls, and Others], and Services), Technology (PCR, Elisa, Direct Assay, and Microbial Culture), Applications (Cell Line Testing, Virus Testing, End Of Production Cells Testing, and Others), and End-users (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

TBionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA, PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.

 

Mycoplasma Testing Market Segment Insights

Kits & reagents segment to account for a key share

Based on products, the global mycoplasma testing market is divided into instruments, kits & reagents, and services. The kits & reagents segment is further classified as PCR assays, nucleic acid detection kits, stains, elimination kits, standards & controls, and others. In 2019, the kits & reagents segment is estimated to account for a large market share. Continuous buying of consumables for detecting mycoplasma in cell culture research work and other applications are key factors for the kits and reagents segment growth. Within the segment, the PCR assays helps in precise mycoplasma identification and gives results within few hours. PCR assays mostly uses electrophoresis, verifying bands of DNA fragments for the detection of mycoplasma. Meanwhile, the instruments segment is estimated to grow significantly during the forecast period owing to wide availability of automated instruments and growing demand for mycoplasma testing. For instance, CFX96 Touch Real-Time PCR Detection System was developed by Bio-Rad, which was meant particularly for PCR detection and flexible with six channels with combination of effective and advanced optical technology.

Mycoplasma Testing Market

PCR segment to hold a significant market share

On the basis of technology, the market is divided into PCR, ELISA, direct assay, and microbial culture. The PCR segment is projected to hold a significant market share during the forecast period. Using this technology, multiple species of mycoplasma are detected by separating other contaminating DNA and ensuring efficient result. Moreover, the rapid detection and ease procedure handling PCR test are major factors pushing to rise demand for the technique. For instance, Merck KGaA developed kit named as LookOut Mycoplasma PCR Detection Kit, which provide facility of detection of Mycoplasma, Acholeplasma and Ureaplasma contamination in cell culture lines and cell-derived biological.

On the other hand, the direct assays segment is estimated to exhibit a high growth rate during the forecast period owing to delivery of effective and accurate results. Meanwhile, the microbial culture segment is also projected to register a high demand due to wide applications of the technology in mycoplasma contamination testing and growing research activities in the biopharmaceutical industry.

Mycoplasma Testing Market

Cell line testing segment held a key share in the market

Based on applications, the global mycoplasma testing market is divided into cell line testing, virus testing, end of production cells testing, and others. The cell line testing segment accounted for a key revenue market share in 2019 and is expected to grow significantly during the forecast period due to increasing research activities in cell culture field and growing mycoplasma contamination in cell culture.

Meanwhile, the end of the production cell testing segment is estimated to exhibit a healthy growth rate over the forecast period due to increase in drug development and discovery clinical trials as well as increasing cell harvest process.  This segment includes techniques such as copy number, mRNA sequencing, and Southern Blotting for genetic analysis of the transgene.

Pharmaceutical & biotechnology companies to constitute a large market share

Based on end-users, the global mycoplasma testing market is divided into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. The pharmaceutical and biotechnology companies segment accounted for a major market share in 2019 and is anticipated to constitute a large market share in the coming years. These companies are increasingly focusing on their research activities to develop new technologies for development and discovery of drug. The companies are involved in quality checking of raw material for management of biological safety. Furthermore, growing prevalence of diseases such as psoriasis and rheumatoid arthritis is a key factor pushing the segment growth.

Mycoplasma Testing Market

North America is expected to dominate the market

On the basis of regions, the global mycoplasma testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. In 2019 the market was dominated by North America and the trend is expected to continue in the coming years. Factor such as increasing investments and spending on healthcare especially from the US government to promote activities based on research in biopharmaceutical industries. In the region, biopharmaceutical players are growing that offer extremely purified cultures for production of therapeutics. Growing R&D sector from the players is expected to propel the regional market growth. On the other hand, the market in Asia Pacific is estimated to expand at a rapid growth rate over the forecast period due to rising awareness and generation of funding initiatives by governments from emerging economies such as India.

Mycoplasma Testing Market

Segments

Segments Covered in the Report

The global mycoplasma testing market has been segmented on the basis of

Products

  • Instruments
  • Kits & Reagents
    • PCR Assays
    • Nucleic Acid Detection Kits
    • Stains
    • Elimination Kits
    • Standards & Controls
    • Others
  • Services

Technology 

  • PCR
  • ELISA
  • Direct Assay
  • Indirect Assay
  • Microbial Culture Techniques
  • Enzymatic Methods

Applications

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

End-users  

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • TBionique Testing Laboratories, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • PromoCell GmbH
  • ATCC (American Type Culture Collection)
  • Biological Industries Israel Beit Haemek Ltd.
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific
  • InvivoGen

Competitive Landscape

Some of the key market players include TBionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA, PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.

Geographical expansions, mergers, acquisitions and new product development are major strategies implemented by key market players. For instance, Lonza extended its mycoplasma detection portfolio by introducing new luminometer Lucetta 2-a product in 2019. Boehringer Ingelheim, in 2018, published its plan for the investment of around 260 million for its new Biological Development Center (BDC) present in Germany at its R&D site. Over the next five years, Merck KGaA planned to invest in R&D around 15 billion as an extra investment to its annual investment of USD 7.2 billion.

Mycoplasma Testing Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Mycoplasma Testing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Mycoplasma Testing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Mycoplasma Testing Market - Supply Chain
  4.5. Global Mycoplasma Testing Market Forecast
     4.5.1. Mycoplasma Testing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Mycoplasma Testing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Mycoplasma Testing Market Absolute $ Opportunity
5. Global Mycoplasma Testing Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Mycoplasma Testing Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Mycoplasma Testing Demand Share Forecast, 2019-2026
6. North America Mycoplasma Testing Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Mycoplasma Testing Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Mycoplasma Testing Demand Share Forecast, 2019-2026
7. Latin America Mycoplasma Testing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Mycoplasma Testing Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Mycoplasma Testing Demand Share Forecast, 2019-2026
8. Europe Mycoplasma Testing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Mycoplasma Testing Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Mycoplasma Testing Demand Share Forecast, 2019-2026
9. Asia Pacific Mycoplasma Testing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Mycoplasma Testing Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Mycoplasma Testing Demand Share Forecast, 2019-2026
10. Middle East & Africa Mycoplasma Testing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Mycoplasma Testing Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Mycoplasma Testing Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Mycoplasma Testing Market: Market Share Analysis
  11.2. Mycoplasma Testing Distributors and Customers
  11.3. Mycoplasma Testing Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. TBionique Testing Laboratories, Inc. Lonza Group Ltd. Merck KGaA PromoCell GmbH ATCC (American Type Culture Collection) Biological Industries Israel Beit Haemek Ltd.  

Segments Covered in the Report

The global mycoplasma testing market has been segmented on the basis of

Products

  • Instruments
  • Kits & Reagents
    • PCR Assays
    • Nucleic Acid Detection Kits
    • Stains
    • Elimination Kits
    • Standards & Controls
    • Others
  • Services

Technology 

  • PCR
  • ELISA
  • Direct Assay
  • Indirect Assay
  • Microbial Culture Techniques
  • Enzymatic Methods

Applications

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

End-users  

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • TBionique Testing Laboratories, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • PromoCell GmbH
  • ATCC (American Type Culture Collection)
  • Biological Industries Israel Beit Haemek Ltd.
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific
  • InvivoGen

Some of the key market players include TBionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA, PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.

Geographical expansions, mergers, acquisitions and new product development are major strategies implemented by key market players. For instance, Lonza extended its mycoplasma detection portfolio by introducing new luminometer Lucetta 2-a product in 2019. Boehringer Ingelheim, in 2018, published its plan for the investment of around 260 million for its new Biological Development Center (BDC) present in Germany at its R&D site. Over the next five years, Merck KGaA planned to invest in R&D around 15 billion as an extra investment to its annual investment of USD 7.2 billion.

Mycoplasma Testing Market

Buy Report